CD79B and aneurysmal bone cyst: In a phase I/II trial involving 80 relapsed or refractory (r/r) de novo systemic DLBCL patients receiving ibrutinib monotherapy, five of the nine patients (55%) with gain-of-function mutation in the CD79B BCR subunit (23% of ABC DLBCLs) responded.